Ambroxol: how a simple cough medicine could treat Parkinson’s

Cure Parkinson's is delighted to announce the large-scale phase 3 clinical trial of ambroxol, a drug currently in use to treat respiratory conditions, will start early in 2023.

The ASPro-PD trial is a world-first phase 3 trial aimed at establishing ambroxol’s potential to slow the progression of Parkinson’s. The trial is a result of collaboration with the Parkinson’s community, driven by Cure Parkinson’s in partnership with Van Andel Institute and the John Black Charitable Foundation

Funded by Cure Parkinson’s alongside its strategic partners, Van Andel Institute and the John Black Charitable Foundation, and by the Parkinson’s Virtual Biotech, the drug discovery and development arm of Parkinson's UK, this trial will be led by Professor Anthony Schapira at UCL and preparations for recruitment of trial participants have already started.

[Lucas]

Hoping that this medicine works! My father has just discovered he has PD, it's been really hard for all of us. May God bless the scientists leading this trials.

[carriemiddleton]

Phase III trials. From a molecular view, it is very possible it could modify GCase. Are GBA genetics being examined in the trials?

[elcyjesus]

Hi i am from India i desperately need this medicine, can someone help how to buy this

[octavioacosta]

How often do you need to take Ambroxol?